Top Markets
Coin of the day
BioPorto A/S BioPorto A/S

BioPorto A/S

BIOPOR
Rank in Stocks #21789
BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker... BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offerings is the neutrophil gelatinase-associated lipocalin (NGAL) test, a precise quantitative particle-enhanced turbidimetric immunoassay designed for use on automated chemistry analyzers. The company further provides monoclonal antibodies essential for scientific, pharmaceutical, and clinical investigations. Additionally, BioPorto produces enzyme-linked immunosorbent assay (ELISA) kits and a versatile rapid assay device tailored for custom lateral flow assay development. Established in 1917, the company is headquartered in Hellerup, Denmark.
Share Price
$0.20243542
Last synced: 2026-08-21
Market Cap
$100.22M
Change (1 day)
2.00%
Change (1 year)
-0.82%
Country
DK
Trade BioPorto A/S (BIOPOR)

Category

Operating Margin for BioPorto A/S (BIOPOR)
Operating Margin as of 2026 TTM: 0.00%
According to BioPorto A/S latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for BioPorto A/S from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
17.69% -
US
20.42% -
US
0.00% -
CN
-10.70% -
US
21.50% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.